Literature DB >> 12938203

Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children.

Elena Samoilovich1, Merja Roivainen, L P Titov, Tapani Hovi.   

Abstract

A total of 32 unimmunized children (median age 5 months) living in an orphanage in Minsk, Belarus, were vaccinated with three doses of oral poliovirus vaccine (OPV) with a 60-day interval between the doses. Blood samples were drawn before the immunizations and 45-50 days after each vaccine dose. Excretion of the vaccine viruses was followed by examining fecal specimens collected weekly after each vaccine dose. All children seroconverted by the second dose of OPV at the latest to all three serotypes of poliovirus but differences were seen regarding the intestinal responses. The strongest responses in both neutralizing antibodies and virus-binding IgA in fecal suspensions were seen toward poliovirus Type 2. Consistent with this, relatively little poliovirus Type 2 excretion was seen after the second and third doses of OPV as compared to that of poliovirus Type 1 or Type 3. The delayed development of functional intestinal immunity against the latter serotypes was associated with relatively weaker intestinal antibody responses compared to poliovirus Type 2. In the case of poliovirus Type 3, about 10% of children were still excreting the vaccine virus 9 weeks after administering the third dose. These results are consistent with epidemiological observations of the serotype-specific efficacy of OPV immunizations. The proportion of specimens showing nonpolio enteric viruses gradually increased through the 6-month study period. This may reflect the possibility that after the first dose of OPV, intensive replication of the vaccine viruses may out compete the nonpolio viruses in the intestines of the vaccinees or, alternatively, mask nonpolio viruses during the cell culture isolation procedure. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938203     DOI: 10.1002/jmv.10480

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.

Authors:  Devasena Gnanashanmugam; Meira S Falkovitz-Halpern; Anthony Dodge; Melanie Fang; Lisa J Wong; Melissa Esparza; Rebecca Hammon; Enrique E Rivas-Merelles; Jose I Santos; Yvonne Maldonado
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

2.  Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.

Authors:  Outi Vaarala; Arja Vuorela; Markku Partinen; Marc Baumann; Tobias L Freitag; Seppo Meri; Päivi Saavalainen; Matti Jauhiainen; Rabah Soliymani; Turkka Kirjavainen; Päivi Olsen; Outi Saarenpää-Heikkilä; Juha Rouvinen; Merja Roivainen; Hanna Nohynek; Jukka Jokinen; Ilkka Julkunen; Terhi Kilpi
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

3.  Assessing the impact of the Lebanese National Polio Immunization Campaign using a population-based computational model.

Authors:  Ali Alawieh; Zahraa Sabra; E Farris Langley; Abdul Rahman Bizri; Randa Hamadeh; Fadi A Zaraket
Journal:  BMC Public Health       Date:  2017-11-25       Impact factor: 3.295

4.  The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses.

Authors:  Megan Auzenbergs; Holly Fountain; Grace Macklin; Hil Lyons; Kathleen M O'Reilly
Journal:  Gates Open Res       Date:  2022-05-05

5.  The evolution of Vp1 gene in enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.

Authors:  Teemu Smura; Soile Blomqvist; Tytti Vuorinen; Olga Ivanova; Elena Samoilovich; Haider Al-Hello; Carita Savolainen-Kopra; Tapani Hovi; Merja Roivainen
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.